vs
Aligos Therapeutics, Inc.（ALGS）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Aligos Therapeutics, Inc.的1171.1倍（$197.9M vs $169.0K）。REPLIGEN CORP净利率更高（6.7% vs -11763.9%，领先11770.6%）。REPLIGEN CORP同比增速更快（13.6% vs -72.1%）。过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -50.7%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ALGS vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1171.1倍
$169.0K
营收增速更快
RGEN
高出85.8%
-72.1%
净利率更高
RGEN
高出11770.6%
-11763.9%
两年增速更快
RGEN
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $197.9M |
| 净利润 | $-19.9M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -12907.7% | 9.0% |
| 净利率 | -11763.9% | 6.7% |
| 营收同比 | -72.1% | 13.6% |
| 净利润同比 | 75.8% | 143.9% |
| 每股收益（稀释后） | $4.23 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGSRGEN
| Q4 25 | $169.0K | $197.9M | ||
| Q3 25 | $741.0K | $188.8M | ||
| Q2 25 | $965.0K | $182.4M | ||
| Q1 25 | $311.0K | $169.2M | ||
| Q4 24 | $606.0K | $174.1M | ||
| Q3 24 | $1.3M | $154.9M | ||
| Q2 24 | $1.1M | $154.1M | ||
| Q1 24 | $694.0K | $151.3M |
净利润ALGSRGEN
| Q4 25 | $-19.9M | $13.3M | ||
| Q3 25 | $-31.5M | $14.9M | ||
| Q2 25 | $-15.9M | $14.9M | ||
| Q1 25 | $43.1M | $5.8M | ||
| Q4 24 | $-82.2M | $-30.3M | ||
| Q3 24 | $-19.3M | $-654.0K | ||
| Q2 24 | $5.1M | $3.3M | ||
| Q1 24 | $-34.9M | $2.1M |
毛利率ALGSRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率ALGSRGEN
| Q4 25 | -12907.7% | 9.0% | ||
| Q3 25 | -3827.4% | 8.9% | ||
| Q2 25 | -1924.0% | 7.6% | ||
| Q1 25 | -6187.5% | 3.9% | ||
| Q4 24 | -3393.2% | -17.7% | ||
| Q3 24 | -1610.5% | -5.1% | ||
| Q2 24 | -2489.5% | 1.0% | ||
| Q1 24 | -3176.7% | 1.3% |
净利率ALGSRGEN
| Q4 25 | -11763.9% | 6.7% | ||
| Q3 25 | -4256.0% | 7.9% | ||
| Q2 25 | -1643.8% | 8.2% | ||
| Q1 25 | 13854.7% | 3.4% | ||
| Q4 24 | -13556.1% | -17.4% | ||
| Q3 24 | -1540.7% | -0.4% | ||
| Q2 24 | 477.0% | 2.2% | ||
| Q1 24 | -5023.5% | 1.4% |
每股收益（稀释后）ALGSRGEN
| Q4 25 | $4.23 | $0.24 | ||
| Q3 25 | $-3.04 | $0.26 | ||
| Q2 25 | $-1.53 | $0.26 | ||
| Q1 25 | $-2.11 | $0.10 | ||
| Q4 24 | $-13.10 | $-0.55 | ||
| Q3 24 | $-3.07 | $-0.01 | ||
| Q2 24 | $0.81 | $0.06 | ||
| Q1 24 | $-5.58 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $53.5M | $2.1B |
| 总资产 | $88.5M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ALGSRGEN
| Q4 25 | $77.8M | $767.6M | ||
| Q3 25 | $99.1M | $748.7M | ||
| Q2 25 | $122.9M | $708.9M | ||
| Q1 25 | $137.9M | $697.2M | ||
| Q4 24 | $56.9M | $757.4M | ||
| Q3 24 | $74.9M | $784.0M | ||
| Q2 24 | $94.5M | $809.1M | ||
| Q1 24 | $112.7M | $780.6M |
总债务ALGSRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALGSRGEN
| Q4 25 | $53.5M | $2.1B | ||
| Q3 25 | $71.8M | $2.1B | ||
| Q2 25 | $101.9M | $2.1B | ||
| Q1 25 | $116.4M | $2.0B | ||
| Q4 24 | $-29.0M | $2.0B | ||
| Q3 24 | $50.1M | $2.0B | ||
| Q2 24 | $67.2M | $2.0B | ||
| Q1 24 | $59.8M | $2.0B |
总资产ALGSRGEN
| Q4 25 | $88.5M | $2.9B | ||
| Q3 25 | $109.8M | $2.9B | ||
| Q2 25 | $134.7M | $2.9B | ||
| Q1 25 | $150.7M | $2.9B | ||
| Q4 24 | $70.1M | $2.8B | ||
| Q3 24 | $88.4M | $2.8B | ||
| Q2 24 | $108.8M | $2.9B | ||
| Q1 24 | $127.9M | $2.8B |
负债/权益比ALGSRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.7M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流ALGSRGEN
| Q4 25 | $-21.7M | $25.7M | ||
| Q3 25 | $-24.3M | $48.1M | ||
| Q2 25 | $-15.5M | $28.6M | ||
| Q1 25 | $-20.9M | $15.0M | ||
| Q4 24 | $-18.4M | $39.2M | ||
| Q3 24 | $-20.1M | $49.3M | ||
| Q2 24 | $-19.5M | $42.2M | ||
| Q1 24 | $-22.7M | $44.7M |
自由现金流ALGSRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M | ||
| Q1 24 | — | $36.4M |
自由现金流率ALGSRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% | ||
| Q1 24 | — | 24.0% |
资本支出强度ALGSRGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 5.5% |
现金转化率ALGSRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | -0.49× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
